Novel Treatment Strategies Utilizing Immune Reactions against Chronic Myelogenous Leukemia Stem Cells

Introduction of tyrosine kinase inhibitors (TKIs) has improved the prognosis of patients with chronic myelogenous leukemia (CML), and treatment-free remission (TFR) is now a treatment goal. However, about half of the patients experience molecular relapse after cessation of TKIs, suggesting that leuk...

Description complète

Enregistré dans:
Détails bibliographiques
Auteur principal: Maiko Matsushita
Format: article
Langue:EN
Publié: MDPI AG 2021
Sujets:
Accès en ligne:https://doaj.org/article/d155489c7fbd45afb4e1e6b21cb70aad
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!